Explained: Is a new era beginning at Biocon with Claire Mazumdar?

New Delhi: This has been a significant milestone in the long-term process of changing the leadership of the company because Kiran Mazumdar-Shaw, the founder and chairperson of the company, has announced her niece, Claire Mazumdar, as her successor.

Reportedly, Mazumdar-Shaw has developed a systematic succession plan, according to which Claire will gradually assume leadership roles in the biopharmaceutical firm. Because it is believed that the transition can be done in phases over the next few years and not right now.

Mazumdar-Shaw explained that she would not be stepping down in the near future, but would like to see that the company is left in good hands in the future.

The present CEO of a US based biotechnology firm, Bicara Therapeutics which specializes in cancer treatments is a 37 year old woman, Claire Mazumdar. Her academic qualifications are well developed as she has degrees with MIT and Stanford and has worked with global biotech and venture firms.

Biocon was started in 1978 and has grown to be one of the largest biopharmaceutical companies in India with its work in biomimics and medicines of low cost. The succession plan is regarded as a step towards ensuring continuity as well as preparing the company to the next step of global expansion.

It is also a significant decision since Mazumdar-Shaw has no children, and wants to retain family participation in the leadership of the company, and at the same time, have professional expertise at the helm.

As Claire Mazumdar is set to play an increasingly important role in the next few years, this shift will be the first step towards a new leadership era at Biocon.

<p>The post Explained: Is a new era beginning at Biocon with Claire Mazumdar? first appeared on Hello Entrepreneurs.</p>